Always enjoy your posts Adam and especially your enthusiasm around the stock's direction and the intel you bring to the forum. One thing that I am still trying to get my head around is the Roxus product and why they have decided to go down this path. I can't help but think that maybe the path to FDA approval may be longer than first thought, so the Roxus option provides a revenue stream to limit the cash burn should the FDA approval process turn out to be longer than first expected as a result of the additional testing that the FDA has requested. Not saying that Roxus is a bad thing and it may turn out to be quite prudent from a cash burn perspective in the long run. The Roxus pathway may also create pre-FDA demand for the product, so that if and when the product finally gets FDA approval it provides some price support should Big Pharma show some interest.
LTP Price at posting:
33.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)